{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:41:13Z","timestamp":1772120473068,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.thromres.2012.06.016","type":"journal-article","created":{"date-parts":[[2012,7,15]],"date-time":"2012-07-15T05:19:06Z","timestamp":1342329546000},"page":"424-428","source":"Crossref","is-referenced-by-count":8,"title":["Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease"],"prefix":"10.1016","volume":"130","author":[{"given":"Alf-\u00c5ge R.","family":"Pettersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Arnesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trine B.","family":"Opstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vibeke","family":"Bratseth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingebj\u00f8rg","family":"Seljeflot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2012.06.016_bb0005","doi-asserted-by":"crossref","first-page":"199S","DOI":"10.1378\/chest.08-0672","article-title":"Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Patrono","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2012.06.016_bb0010","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.ahj.2007.06.013","article-title":"The impact of oral antiplatelet responsiveness on the long-term prognosis after coronary stenting","volume":"154","author":"Foussas","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.thromres.2012.06.016_bb0015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.thromres.2005.10.011","article-title":"Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6months prospective study","volume":"118","author":"Gianetti","year":"2006","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2012.06.016_bb0020","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","article-title":"Aspirin \u201cresistance\u201d and risk of cardiovascular morbidity: systematic review and meta-analysis","volume":"336","author":"Krasopoulos","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.thromres.2012.06.016_bb0025","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.amjcard.2006.05.041","article-title":"Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events","volume":"98","author":"Marcucci","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.thromres.2012.06.016_bb0030","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacc.2008.10.047","article-title":"Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin \u201cresistance\u201d","volume":"53","author":"Santilli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2012.06.016_bb0035","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/01.CIR.92.3.657","article-title":"Coronary plaque disruption","volume":"92","author":"Falk","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2012.06.016_bb0040","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1073\/pnas.96.5.2311","article-title":"Blood-borne tissue factor: another view of thrombosis","volume":"96","author":"Giesen","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.thromres.2012.06.016_bb0045","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1172\/JCI6042","article-title":"Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin","volume":"103","author":"Kahn","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.thromres.2012.06.016_bb0050","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1160\/TH10-11-0711","article-title":"Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects","volume":"106","author":"Siller-Matula","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2012.06.016_bb0055","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/00207230500120294","article-title":"PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy","volume":"16","author":"Smith","year":"2005","journal-title":"Platelets"},{"key":"10.1016\/j.thromres.2012.06.016_bb0060","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1055\/s-0037-1614932","article-title":"Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients","volume":"79","author":"Falciani","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2012.06.016_bb0065","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1538-7836.2007.02372.x","article-title":"Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study","volume":"5","author":"Morange","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2012.06.016_bb0070","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1046\/j.1365-2141.1998.00804.x","article-title":"Monocyte tissue factor-like activity in post myocardial infarction patients","volume":"102","author":"Freeburn","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2012.06.016_bb0075","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.thromres.2003.09.019","article-title":"Soluble tissue factor as predictor of future events in patients with acute myocardial infarction","volume":"111","author":"Seljeflot","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2012.06.016_bb0080","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000073575","article-title":"The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability","volume":"32","author":"Hemker","year":"2002","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.thromres.2012.06.016_bb0085","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/hq0402.105902","article-title":"Tissue plasminogen activator, fibrin D-dimer, and insulin resistance in the relatives of patients with premature coronary artery disease","volume":"22","author":"Mills","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.thromres.2012.06.016_bb0090","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1161\/01.CIR.0000134965.73212.A6","article-title":"Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women","volume":"110","author":"Pradhan","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2012.06.016_bb0095","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2141.1979.tb05855.x","article-title":"Evidence for the platelet specificity of beta-thromboglobulin and studies on its plasma concentration in healthy individuals","volume":"41","author":"Ludlam","year":"1979","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2012.06.016_bb0100","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1053\/euhj.2000.2515","article-title":"Platelet activation: assessment and quantification","volume":"22","author":"Kamath","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2012.06.016_bb0105","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1161\/01.CIR.101.19.2290","article-title":"Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice","volume":"101","author":"Dong","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2012.06.016_bb0110","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0021-9150(96)05980-1","article-title":"Hypothesis: is soluble P-selectin a new marker of platelet activation?","volume":"128","author":"Blann","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.thromres.2012.06.016_bb0115","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/01.CIR.103.4.491","article-title":"Soluble P-selectin and the risk of future cardiovascular events","volume":"103","author":"Ridker","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2012.06.016_bb0120","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1160\/TH10-02-0082","article-title":"24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease","volume":"105","author":"Henry","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2012.06.016_bb0125","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1742-1241.2009.02070.x","article-title":"The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases","volume":"63","author":"Vizioli","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.thromres.2012.06.016_bb0130","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14017430410024324","article-title":"Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design","volume":"38","author":"Pettersen","year":"2004","journal-title":"Scand Cardiovasc J"},{"key":"10.1016\/j.thromres.2012.06.016_bb0135","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2012.06.016_bb0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/09537104.2010.543710","article-title":"Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin","volume":"22","author":"Crescente","year":"2011","journal-title":"Platelets"},{"key":"10.1016\/j.thromres.2012.06.016_bb0145","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/j.1538-7836.2010.04017.x","article-title":"High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events","volume":"8","author":"Breet","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2012.06.016_bb0150","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1160\/TH09-08-0527","article-title":"A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease","volume":"103","author":"Grove","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2012.06.016_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2006.01.046","article-title":"Association of platelet counts on presentation and clinical outcomes in ST-elevation myocardial infarction (from the TIMI Trials)","volume":"98","author":"Ly","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.thromres.2012.06.016_bb0160","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1365-2141.2002.03441.x","article-title":"Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease","volume":"117","author":"Endler","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2012.06.016_bb0165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/cvr\/24.1.19","article-title":"Differences in bleeding time, aspirin sensitivity and adrenaline between acute myocardial infarction and unstable angina","volume":"24","author":"Kristensen","year":"1990","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.thromres.2012.06.016_bb0170","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1067\/mcp.2003.13","article-title":"Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease","volume":"73","author":"Klinkhardt","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.thromres.2012.06.016_bb0175","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/euhj.2001.3237","article-title":"von Willebrand factor and coronary heart disease: prospective study and meta-analysis","volume":"23","author":"Whincup","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.thromres.2012.06.016_bb0180","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1111\/j.1538-7836.2006.02239.x","article-title":"Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS","volume":"4","author":"Fuchs","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2012.06.016_bb0185","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/01.mbc.0000187252.09759.ba","article-title":"Platelet hyper-function in acute coronary syndromes","volume":"16","author":"Harrison","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.thromres.2012.06.016_bb0190","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.112.112094","article-title":"Platelet function testing in patients with coronary artery disease: Is the who and the when any clearer than the what and the what then?","author":"Rade","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2012.06.016_bb0195","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/09537101003735572","article-title":"Effects of aspirin and NO-aspirin (NCX 4016) on platelet function and coagulation in human endotoxemia","volume":"21","author":"Derhaschnig","year":"2010","journal-title":"Platelets"},{"key":"10.1016\/j.thromres.2012.06.016_bb0200","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1182\/blood-2002-11-3566","article-title":"Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb\/IIIa inhibitors and aspirin","volume":"102","author":"Reiter","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2012.06.016_bb0205","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1046\/j.1365-2141.2003.04727.x","article-title":"In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor","volume":"124","author":"Chakroun","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2012.06.016_bb0210","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/09537100903085927","article-title":"The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction","volume":"20","author":"Spiel","year":"2009","journal-title":"Platelets"},{"key":"10.1016\/j.thromres.2012.06.016_bb0215","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2002-10-3188","article-title":"Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis","volume":"101","author":"Dahm","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2012.06.016_bb0220","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1055\/s-0037-1616518","article-title":"Structure and biology of tissue factor pathway inhibitor","volume":"86","author":"Bajaj","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2012.06.016_bb0225","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/338518a0","article-title":"Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor","volume":"338","author":"Girard","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.thromres.2012.06.016_bb0230","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0735-1097(99)00081-9","article-title":"Prognostic significance of elevated hemostatic markers in patients with acute myocardial infarction","volume":"33","author":"Li","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2012.06.016_bb0235","first-page":"349","article-title":"Prognostic significance of markers of thrombin generation in the acute and chronic phases of non cardioembolic ischemic stroke","volume":"48","author":"Soncini","year":"2000","journal-title":"Minerva Cardioangiol"},{"key":"10.1016\/j.thromres.2012.06.016_bb0240","doi-asserted-by":"crossref","first-page":"e000703","DOI":"10.1161\/JAHA.112.000703","article-title":"High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial)","volume":"1","author":"Pettersen","year":"2012","journal-title":"J Am Heart Assoc"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384812002873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384812002873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,30]],"date-time":"2019-06-30T23:36:26Z","timestamp":1561937786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384812002873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0049384812002873"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2012.06.016","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}